These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25576400)

  • 1. Liraglutide as add-on therapy to insulin in type 2 diabetes mellitus: a retrospective, observational study from a daily clinical practice setting in Switzerland.
    Lipowsky C; Sze L; Krull I; Brändle M
    Diabetes Ther; 2015 Mar; 6(1):41-7. PubMed ID: 25576400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Effectiveness of Liraglutide in Association with Patients' Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study.
    Berkovic MC; Bilic-Curcic I; Herman Mahecic D; Gradiser M; Grgurevic M; Bozek T
    Diabetes Ther; 2017 Dec; 8(6):1297-1308. PubMed ID: 29076038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting.
    Kaur P; Mahendru S; Mithal A
    Indian J Endocrinol Metab; 2016; 20(5):595-599. PubMed ID: 27730066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide for treating type 1 diabetes.
    Dejgaard TF; Frandsen CS; Holst JJ; Madsbad S
    Expert Opin Biol Ther; 2016; 16(4):579-90. PubMed ID: 26926662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting.
    Melzer-Cohen C; Chodick G; Naftelberg S; Shehadeh N; Karasik A
    Diabetes Ther; 2020 Jan; 11(1):185-196. PubMed ID: 31808132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
    Guyton J; Jeon M; Brooks A
    Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus.
    Bruinstroop E; Meyer L; Brouwer CB; van Rooijen DE; van Dam PS
    Diabetes Ther; 2018 Jun; 9(3):1369-1375. PubMed ID: 29779196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized controlled trial.
    de Wit HM; Vervoort GM; Jansen HJ; de Galan BE; Tack CJ
    J Intern Med; 2016 Mar; 279(3):283-92. PubMed ID: 26553486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
    Frandsen CS; Dejgaard TF; Holst JJ; Andersen HU; Thorsteinsson B; Madsbad S
    Diabetes Care; 2015 Dec; 38(12):2250-7. PubMed ID: 26486191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.
    Rendell M
    Drugs Today (Barc); 2015 Mar; 51(3):185-96. PubMed ID: 25876562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review.
    Ostawal A; Mocevic E; Kragh N; Xu W
    Diabetes Ther; 2016 Sep; 7(3):411-38. PubMed ID: 27350545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.
    Dejgaard TF; Knop FK; Tarnow L; Frandsen CS; Hansen TS; Almdal T; Holst JJ; Madsbad S; Andersen HU
    BMJ Open; 2015 Apr; 5(4):e007791. PubMed ID: 25838513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom.
    Feher M; Vega-Hernandez G; Mocevic E; Buysse B; Myland M; Power GS; Nystrup Husemoen LL; Kim J; Witte DR
    Diabetes Ther; 2017 Apr; 8(2):417-431. PubMed ID: 28281244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function.
    Usui R; Yabe D; Kuwata H; Fujiwara S; Watanabe K; Hyo T; Yasuhara A; Iwasaki M; Kitatani N; Kuwabara K; Yokota K; Kurose T; Seino Y
    J Diabetes Investig; 2013 Nov; 4(6):585-94. PubMed ID: 24843713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Basal insulin glargine using a basal-bolus regimen in a common clinical practice: observational, non-interventional, multicenter, national project LINDA (Lantus in daily practice - safety and efficacy in basal bolus regimen)].
    Zďarská DJ; Brož J; Křivská B; Rušavý Z; Kvapil M
    Vnitr Lek; 2014 Sep; 60(9):712-9. PubMed ID: 25294758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis.
    Dimitrios P; Michael D; Vasilios K; Konstantinos S; Konstantinos I; Ioanna Z; Konstantinos P; Spyridon B; Asterios K
    Curr Diabetes Rev; 2020; 16(4):313-326. PubMed ID: 31203802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
    Mathieu C; Rodbard HW; Cariou B; Handelsman Y; Philis-Tsimikas A; Ocampo Francisco AM; Rana A; Zinman B;
    Diabetes Obes Metab; 2014 Jul; 16(7):636-44. PubMed ID: 24443830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
    Anholm C; Kumarathurai P; Pedersen LR; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
    Diabetes Obes Metab; 2017 Jun; 19(6):850-857. PubMed ID: 28124822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
    Díaz-Soto G; de Luis DA; Conde-Vicente R; Izaola-Jauregui O; Ramos C; Romero E
    Diabetes Res Clin Pract; 2014 Apr; 104(1):92-6. PubMed ID: 24530118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study.
    Ishii H; Niiya T; Ono Y; Inaba N; Jinnouchi H; Watada H
    Diabetol Metab Syndr; 2017; 9():3. PubMed ID: 28074109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.